Valuation : Kamada Ltd.

Market Cap 1.46B 0 484M 418M 394M 359M 670M 45.75B 675M 4.66B 1.81B 23.39B 1.82B 1.78B 76.84B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.46B 0 484M 418M 394M 359M 670M 45.75B 675M 4.66B 1.81B 23.39B 1.82B 1.78B 76.84B EV / Sales 2026 *
2.42x
EV / Sales 2027 * 2.17x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
1 day+2.01%
1 week+0.16%
Current month+3.55%
1 month+14.07%
3 months+16.32%
6 months-6.83%
Current year+12.26%
1 week 2,400
Extreme 2400
2,546
1 month 2,013
Extreme 2013
2,578
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 58 30/06/2015
Director of Finance/CFO 56 30/12/2017
Chief Operating Officer 54 31/10/2016
Director TitleAgeSince
Director/Board Member 75 12/12/1990
Chairman 77 06/03/2013
Chairman 55 11/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26 Exercice

VP Quality

68,328 0.1184%
05/08/26 Free

Director

30,000 0.0520%
05/08/26 Free

Chairman

30,000 0.0520%
Change 5-day change 1-year change 3-year change Capi.($)
+2.01%+0.16%+5.40%+15.58% 475M
+3.42%+2.22%+46.72%+2.45% 82.26B
-2.24%-5.05%+526.03%+33.98% 61.59B
+0.38%+1.22%-16.23%-34.98% 59.05B
-1.25%-5.30%-1.98%+33.18% 51.23B
+0.92%-1.61%+10.69%+165.47% 48.3B
+3.07%+0.86%+68.41%-16.66% 31.92B
+3.06%-0.69%+52.26%+99.15% 25.34B
+0.20%+1.70%-3.42%+190.03% 22.56B
-0.52%-3.11%+60.78%+115.64% 16.56B
Average +0.91%-2.43%+74.87%+60.39% 39.93B
Weighted average by Cap. +0.80%-2.77%+100.53%+45.36%

Financials

2026 *2027 *
Net sales 606M 0 200M 173M 163M 148M 277M 18.94B 280M 1.93B 749M 9.68B 753M 736M 31.81B 673M 0 223M 192M 181M 165M 308M 21.05B 311M 2.14B 832M 10.76B 837M 818M 35.35B
Net income 84.8M 0 28.06M 24.21M 22.8M 20.78M 38.84M 2.65B 39.13M 270M 105M 1.36B 105M 103M 4.45B 104M 0 34.45M 29.72M 28M 25.51M 47.69M 3.25B 48.04M 332M 129M 1.66B 129M 127M 5.47B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
02/09/26 ILA 2,537.00 +2.01% 200,944
01/09/26 ILA 2,487.00 +1.51% 141,995
31/08/26 ILA 2,450.00 -1.49% 91,012
28/08/26 ILA 2,487.00 +2.43% 59,170
27/08/26 ILA 2,428.00 -4.15% 78,102
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock